-
1.发明申请公开(公告)号：US20200230263A1
公开(公告)日：2020-07-23
申请号：US16824139
申请日：2020-03-19
Applicant: Five Eleven Pharma Inc.
Inventor： Zehui WU , Zhihao ZHA , Futao LIU , Karl PLOESSL , Seok Rye CHOI , Hank F. KUNG
IPC: A61K51/04 , A61B6/03 , C07B59/00 , C07D221/06 , C07D213/64 , C07D405/04 , C07C217/80 , C07D471/04 , C07C323/37
Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
2.发明申请公开(公告)号：US20180344882A1
公开(公告)日：2018-12-06
申请号：US15994474
申请日：2018-05-31
Applicant: Five Eleven Pharma Inc.
Inventor： Zehui WU , Zhihao ZHA , Futao LIU , Karl PLOESSL , Seok Rye CHOI , Hank F. KUNG
IPC: A61K51/04 , A61B6/03 , C07B59/00 , C07D221/06
Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
-
3.发明申请公开(公告)号：US20170189568A1
公开(公告)日：2017-07-06
申请号：US15385490
申请日：2016-12-20
Applicant: Five Eleven Pharma Inc.
Inventor： Hank F. KUNG , Karl PLOESSL , Seok Rye CHOI , Zhihao ZHA , Zehui WU
Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
-
4.发明申请HBED-Bisphosphonates, Radiometal Conjugates and Their Use as Theranostic Agents 审中-公开HBED-Bisphosphonates，Radiometal Conjugates and Their Use as theranostic agents公开(公告)号：US20170022224A1
公开(公告)日：2017-01-26
申请号：US15203602
申请日：2016-07-06
Applicant: Five Eleven Pharma Inc.
Inventor： Hank F. KUNG , Zehui Wu , Seok Rye Choi , Karl PLÖSSL , Zhihao Zha
CPC classification number: C07F9/3873 , A61K51/0489 , A61K51/0497 , C07F9/3817 , C07F9/6515 , C07F9/6524
Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
Abstract translation: 本发明涉及式（I）或式（II）的化合物，它们是用于治疗骨肿瘤和转移的潜在骨成像剂和治疗剂。 用68Ga标记的某些化合物显示出优异的骨吸收和保留性。 本发明还涉及包含药学上可接受的载体和式（I）或式（II）的化合物或其药学上可接受的盐的药物组合物。
-
公开(公告)号：US20220125959A1
公开(公告)日：2022-04-28
申请号：US17605609
申请日：2020-04-27
Applicant: FIVE ELEVEN PHARMA INC.
Inventor： Hank F. KUNG , Zhihao ZHA , Karl PLOESSL , Seok Rye CHOI
Abstract: The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radioactive metal such as [68Ga]or [177Lu]. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or a complex thereof, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20210346526A1
公开(公告)日：2021-11-11
申请号：US17384998
申请日：2021-07-26
Applicant: Five Eleven Pharma Inc.
Inventor： Zehui WU , Zhihao ZHA , Futao LIU , Karl PLOESSL , Seok Rye CHOI , Hank F. KUNG
IPC: A61K51/04 , A61B6/03 , C07B59/00 , C07D221/06 , C07D213/64 , C07D405/04 , C07C217/80 , C07D471/04 , C07C323/37
Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
